natgillin/translations-raw huggingface dataset:
If there are less then 3 days before your next dose is due, skip the dose and inject the next one on your regular scheduled day. 
Ako je do sljedeće doze preostalo manje od 3 dana, preskočite propuštenu dozu i injicirajte sljedeću prema uobičajenom rasporedu.
Combination therapy with metformin and sulphonylurea In an active controlled study of 78 weeks duration, dulaglutide was compared to insulin glargine, both on a background of metformin and a sulphonylurea. 
Kombinirana terapija s metforminom i sulfonilurejom U aktivno kontroliranom ispitivanju u trajanju od 78 tjedana, dulaglutid se uspoređivao s inzulinom glarginom; oba su se lijeka primjenjivala uz osnovno liječenje metforminom i sulfonilurejom.
Skin and subcutaneous tissue disorders 
Poremećaji kože i potkožnog tkiva angioedem#
Cumulative reporting of gastrointestinal events up to 104 weeks with dulaglutide 0.75mg and 1.5 mg, respectively, included nausea (12.9% and 21.2 %), diarrhoea (10.7% and 13.7 %) and vomiting (6.9% and 11.5 %). 
Kumulativno prijavljeni gastrointestinalni događaji do 104. tjedna uz primjenu dulaglutida u dozi od 0,75 mg odnosno 1,5 mg uključivali su mučninu (12,9% odnosno 21,2%), proljev (10,7% odnosno 13,7%) i povraćanje (6,9% odnosno 11,5%).
You should see a doctor immediately if you experience such symptoms. 
U slučaju pojave takvih simptoma morate se odmah javiti liječniku.
Do not recycle the filled sharps container. 
• Pun spremnik za oštre predmete ne smije se reciklirati.
Dehydration 
dehidracija
Statistically significant reductions in Cmax of 26 % and 13 % and delays in tmax of 2 and 0.30 hours were observed for norelgestromin and ethinyl estradiol, respectively. 
Primijećeno je statistički značajno smanjenje Cmax od 26% i produljenje tmax od 2 sata za norelgestromin te statistički značajno smanjenje Cmax od 13% i produljenje tmax od 0,30 sati za etinilestradiol.
INFORMATION IN BRAILLE TRULICITY 1.5 mg 
16. PODACI NA BRAILLEOVOM PISMU TRULICITY 1,5 mg
The mean absolute bioavailability of dulaglutide following single-dose subcutaneous administration of single 1.5 mg and 0.75 mg doses was 47 % and 65%, respectively. 
Srednja vrijednost apsolutne bioraspoloživosti dulaglutida nakon jednokratne supkutane primjene jedne doze od 1,5 mg odnosno 0,75 mg iznosila je 47% odnosno 65%.
atrioventricular block (AVB) 
Pretrage sinusna tahikardija, atrioventrikularni blok prvog stupnja (AVB)
The severe hypoglycaemia event incidences were 2.4% and 3.4%, and rates were 0.05 and 0.06 events/patient/year. 
Incidencije događaja teške hipoglikemije iznosile su 2,4% odnosno 3,4%, dok su stope iznosile 0,05 odnosno 0,06 događaja po bolesnik-godini.
For dulaglutide 0.75 mg, adverse reaction met frequency for next lower incidence grouping. 
Kod dulaglutida u dozi od 0,75 mg, učestalost nuspojave odgovarala je sljedećoj nižoj kategoriji incidencije.
Read the “Instructions for Use” for the syringe carefully before using Trulicity. 
Pažljivo pročitajte 'Upute za uporabu' štrcaljke prije nego što primijenite Trulicity.
When a single dose of dulaglutide and metoprolol were coadministered, the AUC and Cmax of metoprolol increased by19 % and 32 %, respectively. 
Kada su istodobno primijenjene jedna doza dulaglutida i metoprolola, AUC metoprolola povećao se za 19%, a Cmax za 32%.
What if there is a drop of liquid on the tip of the needle when I remove the base cap? 
Što ako se na vrhu igle nalazi kapljica tekućine nakon što skinem zatvarač baze?
ABOUT TRULICITY PRE-FILLED SYRINGE 
O TRULICITY NAPUNJENOJ ŠTRCALJKI
Treatment with Trulicity 1.5mg in combination with glimepiride resulted in a statistically significant reduction in HbA1c compared to placebo with glimepiride at 24 weeks. 
Liječenje lijekom Trulicity 1,5 mg u kombinaciji s glimepiridom dovelo je do statistički značajnog smanjenja razine HbA1c u 24. tjednu u usporedbi s placebom u kombinaciji s glimepiridom.
Read the “Instructions for Use” for the pen carefully before using Trulicity. 
Pažljivo pročitajte 'Upute za uporabu' brizgalice prije nego što primijenite Trulicity.
Do not use this medicine after the expiry date which is stated on the syringe label and on the carton after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici brizgalice i kutiji iza oznake „EXP” ili „Rok valjanosti”.
These studies included 3,808 dulaglutide treated patients, of whom 2,250 were treated with Trulicity 1.5 mg weekly and 1,558 were treated with Trulicity 0.75 mg weekly. 
U navedena je ispitivanja bilo uključeno 3808 bolesnika liječenih dulaglutidom: 2250 bolesnika primalo je Trulicity u dozi od 1,5 mg jedanput na tjedan, a njih 1558 primalo je Trulicity u dozi od 0,75 mg jedanput na tjedan.
Two cases of severe hypoglycaemia were observed with Trulicity 1.5mg and two cases of severe hypoglycaemia were observed with insulin glargine. 
Zabilježena su dva slučaja teške hipoglikemije uz Trulicity 1,5 mg i dva slučaja teške hipoglikemije uz inzulin glargin.
Combination therapy with sulphonylurea 
Kombinirana terapija sa sulfonilurejom
Treatment with dulaglutide resulted in significant reductions from baseline in fasting blood glucose. 
Liječenje dulaglutidom dovelo je do značajnih smanjenja glukoze u krvi natašte u odnosu na početne vrijednosti.
In the same study, a single 1.5 mg dose of dulaglutide appeared to increase maximal insulin secretion from the β-cells, and to enhance β-cell function in subjects with type 2 diabetes mellitus as compared with placebo. 
1,5 mg naizgled povećala maksimalno lučenje inzulina iz β-stanica i poboljšala funkciju β-stanica u bolesnika sa šećernom bolešću tipa 2 u odnosu na placebo.
UNCAP 2. 
PRILOG II.
In a 52 week study, Trulicity 1.5 mg and 0.75 mg were compared to titrated insulin glargine as add-on to prandial insulin lispro to evaluate the effect on glycaemic control and safety of patients with moderate to severe chronic kidney disease (eGFR [by CKD-EPI] <60 and ≥15 mL/min/1.73 m2). 
52-tjednom su se ispitivanju Trulicity 1,5 mg i Trulicity 0,75 mg uspoređivali s titriranim inzulinom glarginom kao dodatkom prandijalnom inzulinu lispro radi ocjene učinka na regulaciju glikemije i sigurnosti u bolesnika s umjerenom do teškom kroničnom bubrežnom bolešću (eGFR [prema CKD-EPI] < 60 i ≥ 15 ml/min/1,73 m2).
The mean apparent clearance of dulaglutide 0.75 mg and 1.5 mg at steady state was 0.111 L/h and 0.107 L/h with an elimination half-life of 4.5 and 4.7 days, respectively. 
Srednji prividni klirens dulaglutida od 0,75 mg odnosno 1,5 mg u stanju dinamičke ravnoteže iznosio je 0,111 l/h odnosno 0,107 l/h, uz poluvijek eliminacije od 4,5 odnosno 4,7 dana.
EU/1/14/956/007 4 pre-filled pens 
EU/1/14/956/007 4 napunjene brizgalice
Combination therapy with titrated basal insulin, with or without metformin In a 28 week placebo controlled study, Trulicity1.5 mg was compared to placebo as add-on to titrated basal insulin glargine (88% with and 12% without metformin) to evaluate the effect on glycaemic control and safety. 
Kombinirana terapija s titriranim bazalnim inzulinom, uz metformin ili bez njega U 28-tjednom placebom kontroliranom ispitivanju uspoređivali su se Trulicity 1,5 mg i placebo kao dodatak titriranom bazalnom inzulinu glarginu (88% uz metformin, 12% bez metformina) radi ocjene učinka na regulaciju glikemije i sigurnost.
The incidence of documented symptomatic hypoglycaemia when dulaglutide 1.5 mg was used with sulphonylurea alone was 11.3% and the rate was 0.90 events/patient/year, and there were no episodes of severe hypoglycaemia. 
Incidencija dokumentirane simptomatske hipoglikemije kada se dulaglutid u dozi od 1,5 mg primjenjivao samo sa sulfonilurejom iznosila je 11,3%, dok je stopa iznosila 0,90 događaja po bolesnik-godini, a nije bilo epizoda teške hipoglikemije.
When used alone, the recommended dose is 0.75 mg once a week. 
Kada se lijek primjenjuje samostalno, preporučena doza iznosi 0,75 mg jedanput na tjedan.
Coadministration of dulaglutide with atorvastatin decreased Cmax and AUC(0-∞) up to 70 % and 21 %, respectively, for atorvastatin and its major metabolite o-hydroxyatorvastatin. 
Istodobna primjena dulaglutida s atorvastatinom smanjila je Cmax atorvastatina i njegovog glavnog metabolita o-hidroksiatorvastatina za do 70%, a njihov AUC(0-∞) za do 21%.
At the end of the 28 week treatment period the dose was 65 units/day and 51 units/day, for patients receiving placebo and Trulicity 1.5 mg, respectively. 
Na kraju 28-tjednog razdoblja liječenja, doza je bila 65 jedinica/dan za bolesnike koji su primali placebo te 51 jedinica/dan za bolesnike liječene lijekom
- Feeling less hungry (decreased appetite) - Indigestion - Constipation - Gas (flatulence) - Bloating of the stomach - Gastroesophageal reflux disease - a disease caused by stomach acid coming up into the tube from your stomach to your mouth - Burping - Feeling tired - Increased heart rate - Slowing of the electrical currents in the heart 
- probavne tegobe - zatvor - vjetrovi (flatulencija) - nadutost - gastroezofagealna refluksna bolest - bolest uzrokovana vraćanjem želučane kiseline iz želuca do usta kroz jednjak - podrigivanje
You should use it on the same day each week if you can. To help you remember, you may wish to tick the day of the week when you inject your first dose on the box that your syringe comes in, or on a calendar. 
Da biste se lakše sjetili primijeniti lijek, možete označiti dan u tjednu kada ste injicirali prvu dozu na kutiji štrcaljke ili na kalendaru.
Combination therapy with metformin and pioglitazone In a placebo and active (exenatide twice daily) controlled study, both in combination with metformin and pioglitazone, Trulicity 1.5 mg and 0.75 mg demonstrated superiority for HbA1c reduction in comparison to placebo and exenatide, accompanied by a significantly a greater percentage of patients achieving HbA1c targets of < 7.0 % or ≤ 6.5 % 
U placebom i aktivnim lijekom (eksenatid dvaput na dan) kontroliranom ispitivanju, u oba slučaja u kombinaciji s metforminom i pioglitazonom, Trulicity od 1,5 mg i 0,75 mg doveo je do superiornog smanjenja HbA1c u usporedbi s placebom i eksenatidom, sa značajno većim postotkom bolesnika koji su postigli ciljne vrijednosti HbA1c od < 7,0% ili ≤ 6,5%.
The Trulicity treatment arm included patients ≥ 65 years (n = 2,619) and ≥ 75 years (n = 484), 
Skupina liječena lijekom Trulicity uključivala je bolesnike u dobi od ≥ 65 godina (n = 2619) i one u dobi od ≥ 75 godina (n = 484) te bolesnike s blagim (n = 2435), umjerenim (n = 1031) ili teškim
At 52 weeks, Trulicity 1.5 mg demonstrated superior lowering in HbA1c to insulin glargine which was maintained at 78 weeks; whereas lowering in HbA1c with Trulicity 0.75 mg was non-inferior to insulin glargine. 
52. tjednu, Trulicity u dozi od 1,5 mg pokazao se superiornim u odnosu na inzulin glargin u smanjenju razine HbA1c, koje se održalo do 78. tjedna; nasuprot tome, smanjenje razine HbA1c uz Trulicity u dozi od 0,75 mg bilo je neinferiorno u odnosu na inzulin glargin.
You should use it on the same day each week if you can. To help you remember, you may wish to tick the day of the week when you inject your first dose on the box that your pen comes in, or on a calendar. 
Da biste se lakše sjetili primijeniti lijek, možete označiti dan u tjednu kada ste injicirali prvu dozu na kutiji brizgalice ili na kalendaru.
Ten patients reported severe hypoglycaemia with Trulicity 1.5 mg, seven with Trulicity 0.75 mg, and fifteen with insulin glargine. 
Deset bolesnika prijavilo je tešku hipoglikemiju uz Trulicity 1,5 mg, sedam uz Trulicity 0,75 mg i petnaest uz inzulin glargin.
1 UNCAP Pull off and discard the needle cover. 
• Skinite i bacite pokrov igle.
These changes are not clinically relevant. 
Navedene promjene nisu klinički značajne.
A greater percentage of patients achieved HbA1c targets of < 7.0 % or ≤ 6.5 % at 26 weeks and < 7.0 % at 52 weeks than with insulin glargine. 
Veći je postotak bolesnika postigao ciljne vrijednosti HbA1c od < 7,0% ili ≤ 6,5% u 26. tjednu i < 7,0% u 52. tjednu uz Trulicity nego uz inzulin glargin.
• When refrigeration is not possible, you can keep your pen at room temperature (below 30°C) for up to a total of 14 days. 
• Ako je ne možete odložiti u hladnjak, štrcaljku možete čuvati na sobnoj temperaturi (ispod 30ºC)
LIST OF EXCIPIENTS Excipients: Sodium citrate; citric acid, anhydrous; mannitol; polysorbate 80; water for injections 
Pomoćne tvari: natrijev citrat, bezvodna citratna kiselina, manitol, polisorbat 80, voda za injekcije
Dulaglutide delays gastric emptying and has the potential to impact the rate of absorption of concomitantly administered oral medicinal products. 
Dulaglutid odgađa pražnjenje želuca, što može utjecati na brzinu apsorpcije istodobno primijenjenih peroralnih lijekova.
This medicinal product contains less than 1 mmol sodium (23 mg) per 1.5 mg dose, i.e. essentially ‘sodium- free'. 
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po dozi od 1,5 mg, tj. zanemarive količine natrija.
Trulicity is to be injected subcutaneously in the abdomen, thigh or upper arm. 
Trulicity se primjenjuje supkutanom injekcijom u abdomen, bedro ili nadlakticu.
- you are taking a sulphonylurea or insulin for your diabetes, as low blood sugar (hypoglycaemia) can occur. 
- ako za liječenje šećerne bolesti uzimate sulfonilureju ili inzulin, jer može doći do pada razine šećera u krvi (hipoglikemije).
When Trulicity is added to existing metformin and/or sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy, the current dose of metformin and/or SGLT2i can be continued. 
Kada se Trulicity dodaje postojećoj terapiji metforminom i/ili inhibitorom suprijenosnika natrija i glukoze 2 (engl. sodium-glucose co-transporter 2 inhibitor, SGLT2i), može se nastaviti s primjenom dotadašnje doze metformina i/ili inhibitora SGLT2.
You can use your syringe at any time of the day, with or without meals. 
Štrcaljku možete primijeniti u bilo koje doba dana, neovisno o obrocima.
This medicine contains less than 1 mmol sodium (23 mg) per 0.75 mg or 1.5 mg, that is to say essentially ‘sodium-free'. 
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po dozi od 0,75 mg ili 1,5 mg, tj. zanemarive količine natrija.
Talk to your doctor if you would like to or are breast-feeding before taking this medicine. 
Prije nego što uzmete ovaj lijek razgovarajte sa svojim liječnikom ako želite dojiti ili već dojite.
Sitagliptin 100 mg once daily (n=315) 
Sitagliptin 100 mg jedanput na dan (n=315)
Each pen delivers only one dose. 
Jedna brizgalica isporučuje samo jednu dozu.
Sitagliptin tmax increased approximately 0.5 hours following coadministration with dulaglutide compared to sitagliptin alone. 
Nakon istodobne primjene s dulaglutidom, tmax sitagliptina produljio se za približno 0,5 sati u odnosu na vrijednost nakon primjene samog sitagliptina.
You should see a doctor immediately if you experience symptoms such as rashes, itching and rapid swelling of the tissues of the neck, face, mouth or throat, hives and difficulties breathing. 
- teške alergijske reakcije (anafilaktičke reakcije, angioedem) Morate se odmah javiti svom liječniku ako primijetite simptome kao što su osipi, svrbež i naglo oticanje tkiva vrata, lica, usta ili grla, koprivnjača i otežano disanje.
Rare: may affect up to 1 in 1,000 people - Severe allergic reactions (anaphylactic reactions, angioedema). 
Manje česte: mogu se javiti u do 1 na 100 osoba - reakcije na mjestu injekcije (npr. osip ili crvenilo)
At 28 weeks, treatment with once weekly Trulicity 1.5 mg resulted in a statistically significant reduction in HbA1c compared to placebo and a significantly greater percentage of patients achieving HbA1c targets of < 7.0 % and ≤ 6.5 % (Table 9). 
U 28. tjednu, liječenje lijekom Trulicity 1,5 mg jedanput na tjedan dovelo je do statistički značajnog smanjenja razine HbA1c u usporedbi s placebom te značajno većeg postotka bolesnika koji su postigli ciljnu vrijednost HbA1c od < 7,0% i ≤ 6,5% (Tablica 9).
Insulin glargine+ once daily (n=296) 
Inzulin glargin+ jedanput na dan (n=296)
Dulaglutide was studied in a 52 week active controlled monotherapy study in comparison to metformin. 
Dulaglutid je ispitivan u aktivno kontroliranom ispitivanju u kojem je monoterapija uspoređivana s metforminom u trajanju od 52 tjedna.
Trulicity is injected under the skin (subcutaneous injection) of your stomach area (abdomen) or upper leg (thigh). 
Trulicity se injicira potkožno (supkutana injekcija) u područje trbuha (abdomena) ili natkoljenice (bedra).
EU/1/14/956/002 4 pre-filled pens 
EU/1/14/956/002 4 napunjene brizgalice
Table 6: Results of a 24 week placebo controlled study of dulaglutide as add-on to glimepiride 
Tablica 6: Rezultati 24-tjednog placebom kontroliranog ispitivanja dulaglutida kao dodatka glimepiridu
Use in patients with renal impairment 
Primjena u bolesnika s oštećenjem funkcije bubrega
Insulin glargine+ once daily (n=194) 
Inzulin glargin+ jedanput na dan (n=194)
Remove the needle from the skin. 
Izvadite iglu iz kože.
Hypoglycaemia* (when used in combination with insulin, glimepiride, metformin† or metformin plus glimepiride) 
Poremećaji metabolizma i prehrane hipoglikemija* (kada se primjenjuje u kombinaciji s inzulinom, glimepiridom, metforminom† ili metforminom uz glimepirid)
The mean volume of distribution after subcutaneous administration of dulaglutide 0.75 mg and 1.5 mg at steady state in patients with type 2 diabetes mellitus were approximately 19.2 L and 17.4 L. 
0,75 mg odnosno 1,5 mg u stanju dinamičke ravnoteže u bolesnika sa šećernom bolešću tipa 2 iznosila je približno 19,2 l odnosno 17,4 l.
Within each incidence grouping, adverse reactions are presented in order of decreasing frequency. 
Unutar svake skupine učestalosti nuspojave su prikazane u padajućem nizu prema učestalosti.
It is not known if dulaglutide could harm your unborn child. Women who could become pregnant should use contraception during treatment with dulagutide. 
Žene koje bi mogle zatrudnjeti moraju koristiti kontracepciju tijekom liječenja dulaglutidom.
Insulin glargine+ once daily (n=262) 
Inzulin glargin+ jedanput na dan (n=262)
• Store your syringe in the refrigerator. 
• Štrcaljku čuvajte u hladnjaku.
Treatment with Trulicity 1.5 mg resulted in similar lowering of HbA1c and patients achieving HbA1c targets of < 7.0 % and ≤ 6.5 % compared to liraglutide. 
Liječenje lijekom Trulicity od 1,5 mg dovelo je do sličnog smanjenja vrijednosti HbA1c i udjela bolesnika koji su postigli ciljnu vrijednost HbA1c od < 7,0% i ≤ 6,5% u usporedbi s liraglutidom.
2 INSERT 
2 NAMJESTITE
• Keep the syringe out of sight and reach of children. 
• Štrcaljku čuvajte izvan pogleda i dohvata djece.
No dose adjustment for oral contraceptives is required when given together with dulaglutide. 
Nije potrebno prilagođavati dozu oralnih kontraceptiva kada se primjenjuju istodobno s dulaglutidom.
Common: may affect up to 1 in 10 people - Hypoglycaemia is common when dulaglutide is used alone, or with both metformin and pioglitazone together, or with a sodium-glucose co-transporter 2 inhibitor (SGLT2i) with or without metformin. 
- hipoglikemija, koja je česta kada se dulaglutid primjenjuje samostalno, u kombinaciji s metforminom i pioglitazonom ili u kombinaciji s inhibitorom suprijenosnika natrija i glukoze 2 (engl. sodium-glucose co-transporter 2 inhibitor, SGLT2i), s metforminom ili bez njega
The incidences of documented symptomatic hypoglycaemia when dulaglutide 0.75 mg and 1.5 mg, respectively, were used in combination with a sulphonylurea and metformin were 39.0% and 40.3% and the rates were 1.67 and 1.67 events/patient/year. 
Incidencija dokumentirane simptomatske hipoglikemije kod primjene dulaglutida u kombinaciji sa sulfonilurejom i metforminom iznosila je 39,0% za dozu od 0,75 mg, odnosno 40,3% za dozu od 1,5 mg, dok su stope iznosile 1,67 odnosno 1,67 događaja po bolesnik-godini.
• Store the syringe in the original package in order to protect from light. 
• Štrcaljku čuvajte u originalnom pakiranju radi zaštite od svjetlosti.
There was a general increase in tmax of dulaglutide with increased hepatic impairment. 
S povećanjem oštećenja jetrene funkcije u načelu se povećavao i tmax dulaglutida.
Table 7: Results of a 24 week placebo controlled study of dulaglutide as add-on to SGLT2i therapy 
Tablica 7: Rezultati 24-tjednog placebom kontroliranog ispitivanja dulaglutida kao dodatka terapiji inhibitorom SGLT2
Treatment with Trulicity 1.5 mg and 0.75 mg resulted in a superior reduction in HbA1c compared to sitagliptin at 52 weeks, accompanied by a significantly greater proportion of patients achieving HbA1c targets of < 7.0 % and ≤ 6.5 %. 
Liječenje lijekom Trulicity od 1,5 mg i 0,75 mg dovelo je do superiornog smanjenja HbA1c u 52. tjednu u usporedbi sa sitagliptinom, sa značajno većim udjelom bolesnika koji su postigli ciljne vrijednosti HbA1c od < 7,0% i ≤ 6,5%.
4 pre-filled syringes of 0.5 ml solution 
4 napunjene štrcaljke s 0,5 ml otopine
Dispose of the pen as directed by your doctor, pharmacist or nurse. 
Zbrinite brizgalicu sukladno uputama koje ste dobili od liječnika, ljekarnika ili medicinske sestre.
Table 9: Results of a 28 week study of dulaglutide compared to placebo as add-on to titrated insulin glargine 
Tablica 9: Rezultati 28-tjednog ispitivanja dulaglutida kao dodatka titriranom inzulinu glarginu u odnosu na placebo
Dulaglutide 1.5 mg once weekly and insulin glargine (n=150) 
Dulaglutid 1,5 mg jedanput na tjedan i inzulin glargin (n=150)
50019, Sesto Fiorentino 
Via Gramsci 731/733 50019, Sesto Fiorentino Firenca (FI) Italija
Uncommon: may affect up to 1 in 100 people - Injection site reactions (e.g. rash or redness) - Allergic reactions (hypersensitivity) (e.g. swelling, raised itchy skin rash (hives)) - Dehydration, often associated with nausea, vomiting and/or diarrhoea - Gallstones - Inflamed gallbladder 
- alergijske reakcije (preosjetljivost) (npr. oticanje, uzdignut kožni osip koji svrbi (koprivnjača)) - dehidracija, često povezana s mučninom, povraćanjem i/ili proljevom - žučni kamenci
Dulaglutide also slows gastric emptying. 
Dulaglutid također usporava pražnjenje želuca.
Treatment with Trulicity 0.75 mg or Trulicity 1.5 mg in combination with SGLT2i therapy resulted in a statistically significant reduction in HbA1c compared to placebo with SGLT2i therapy at 24 weeks. 
Liječenje lijekom Trulicity 0,75 mg ili Trulicity 1,5 mg u kombinaciji s terapijom inhibitorom SGLT2 dovelo je do statistički značajnog smanjenja razine HbA1c u
Dispose of the pen in a sharps container or as directed by your doctor, pharmacist or nurse. 
• Štrcaljku odložite u spremnik za oštre predmete ili zbrinite sukladno uputama svoga liječnika, ljekarnika ili medicinske sestre.
No patients reported cases of severe hypoglycaemia with Trulicity 1.5 mg, six with Trulicity 0.75 mg, and seventeen with insulin glargine. 
Nije prijavljen nijedan slučaj teške hipoglikemije uz Trulicity 1,5 mg, ali ih je prijavljeno šest uz Trulicity 0,75 mg i sedamnaest uz inzulin glargin.
Cases of anaphylactic reaction have been rarely reported with marketed use of dulaglutide. 
Kod primjene dulaglutida nakon stavljanja lijeka u promet rijetko su prijavljeni slučajevi anafilaktičke reakcije.
No dose adjustment of paracetamol is necessary when administered with dulaglutide. 
Nije potrebno prilagođavati dozu paracetamola kada se primjenjuje istodobno s dulaglutidom.
Sitagliptin 100 mg once daily (n=315) †† multiplicity adjusted 1-sided p-value < 0.025, for superiority of dulaglutide compared to sitagliptin, assessed only for HbA1c at 52 and 104 weeks ‡‡ multiplicity adjusted 1-sided p-value < 0.001 for superiority of dulaglutide compared to placebo, 
Sitagliptin 100 mg jedanput na dan (n=315) †† jednostrana p-vrijednost prilagođena za multiplicitet < 0,025, za superiornost dulaglutida u usporedbi sa sitagliptinom, ocijenjena samo za HbA1c u 52. i 104. tjednu ‡‡ jednostrana p-vrijednost prilagođena za multiplicitet < 0,001, za superiornost dulaglutida u usporedbi s placebom, ocijenjena samo za HbA1c
Multi-pack: 12 (3 packs of 4) pre-filled syringes of 0.5 ml solution. 
Višestruko pakiranje: 12 (3 pakiranja s 4) napunjenih štrcaljki s 0,5 ml otopine.